サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791761

オピオイド使用障害の世界市場

Opioid Use Disorder

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
オピオイド使用障害の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

オピオイド使用障害の世界市場は2030年までに106億米ドルに達する見込み

2024年に57億米ドルと推定されるオピオイド使用障害の世界市場は、2024～2030年の分析期間においてCAGR 10.9%で成長し、2030年には106億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるブプレノルフィン医薬品は、CAGR 12.5%を記録し、分析期間終了時には54億米ドルに達すると予測されます。ナルトレキソン医薬品セグメントの成長率は、分析期間中CAGR 8.9％と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 9.8％で成長予測

米国のオピオイド使用障害市場は2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.8％と8.7％と予測されています。欧州では、ドイツがCAGR 8.3%で成長すると予測されています。

世界のオピオイド使用障害市場- 主要動向と促進要因のまとめ

オピオイド使用障害が持続的な世界的健康危機であり、スケーラブルな介入を必要とするのはなぜか？

オピオイド使用障害（OUD）は、特に北米において、フェンタニルなどの合成オピオイドが前例のない過剰摂取率を引き起こしていることから、世界的に公衆衛生上の重大な緊急事態に発展しています。OUDの慢性的で再発しやすい性質と、社会経済的な影響が広範囲に及ぶことから、包括的な治療インフラと長期的なケアの解決策が緊急に求められています。OUDの蔓延に対する認識が著しく高まる一方で、違法薬物の使用だけでなく、疼痛管理のためのオピオイドの過剰処方にも関わるこの危機の複雑さも増しています。世界全体で数百万人が影響を受けており、ヘルスケアシステムは、薬物補助療法（MAT）、行動療法、ハームリダクション、社会的支援を組み合わせた統合的なマルチモーダル・アプローチを採用する必要に迫られています。依存症を取り巻く偏見、ヘルスケアへのアクセス格差、薬物使用の犯罪化は、依然として効果的な介入戦略の妨げとなっています。しかし、公衆衛生資金の増加、治療センターの利用可能性の拡大、治療可能な医学的状態としての依存症に対する認識の変化により、回復を支援する環境が整いつつあります。このような背景から、政府、ヘルスケアプロバイダー、民間企業は、オピオイド依存の生理学的側面と心理学的側面の両方に対処する、拡張可能でエビデンスに基づく解決策を優先しており、OUD治療市場は拡大しています。

治療方法の進歩は、回復の成果をどのように形成しているか？

情勢は急速に進化しており、治療法の有効性、安全性、アクセシビリティの向上に重点を置いた技術革新が進んでいます。薬物補助療法（MAT）は依然としてOUD管理の要であり、メサドン、ブプレノルフィン、ナルトレキソンが渇望を抑え、オピオイドの作用を遮断し、回復をサポートするために広く使用されています。最近の動向では、持続的な薬物送達を確保し、投与回数を減らし、長期的な回復において重要な要素である服薬アドヒアランスを改善する徐放性製剤や埋め込み型デバイスが開発されています。また、オピオイド依存とうつ病や不安症などの併発疾患の両方に対応する新しい併用療法も登場しています。デジタル治療薬と遠隔医療ベースのカウンセリング・プラットフォームは、特にCOVID-19以降に台頭してきており、遠隔モニタリング、治療へのアクセス、アドヒアランスの追跡を可能にしています。ウェアラブルバイオセンサーや、リアルタイムのフィードバックや再発アラートを提供するモバイルアプリは、臨床環境外で患者をサポートするために研究されています。さらに、薬物が効果を発揮する前にオピオイド受容体を遮断するワクチンや拮抗薬の研究も進んでおり、将来の予防戦略に期待が寄せられています。こうした進歩は、患者の転帰を改善するだけでなく、従来のインフラが不足しているような、十分な治療を受けられない地域や地方における治療の選択肢を広げることにもつながっています。

市場の需要とアクセシビリティに影響を与えている制度的・地域的要因とは？

オピオイド使用障害治療ソリューションに対する需要は、ヘルスケア・インフラ、政策の枠組み、依存症に対する社会文化的な考え方の違いにより、地域によって大きく異なります。オピオイド危機が流行レベルに達している米国とカナダでは、MATへのアクセス拡大、ナロキソンの配布や安全な注射場所のような害軽減サービス、プライマリ・ケアや救急サービスへのOUD治療の統合に重点が置かれています。これらの国々では、新しい治療薬に対する政府の強力な資金援助や、迅速な承認や償還プログラムなどの規制当局の支援も行われています。これとは対照的に、開発途上国では、制限的な薬物政策や資金不足のヘルスケアシステムのために、疼痛管理のためのオピオイドとOUD治療の両方へのアクセスが制限されていることが多いです。スティグマは依然として世界の障壁であり、しばしば個人が治療を求めたり、政府が依存症治療に投資することを躊躇させる。しかし、WHOやUNODCのような組織による世界の取り組みが、特に東欧、ラテンアメリカ、アジアの一部において、意識向上と能力開発の努力を後押ししています。一方、いくつかの国で刑事司法改革が行われ、薬物使用者を収監ではなく治療に向かわせることで、OUDの解決策に対する制度的需要が拡大しています。このような地域格差や政策転換は、OUD治療製品やサービスの市場がどこで、どのように開拓されているかを形成する上で、極めて重要な役割を果たしています。

オピオイド使用障害市場の成長を促進する主な要因とは？

オピオイド使用障害市場の成長は、有病率の上昇、治療パラダイムの進化、技術統合、政策転換に関連するいくつかの要因によってもたらされます。重要な原動力は、世界のオピオイド中毒と関連死の増加であり、これが緊急のヘルスケア介入と持続的な公衆衛生資金の投入を促しています。OUD治療のゴールドスタンダードとして薬物療法が広く受け入れられていることが、メタドン、ブプレノルフィン、ナルトレキソン製剤、特にアドヒアランスを向上させる長時間作用型の注射剤に対する需要を促進しています。遠隔医療サービスの拡大により、特に農村部や十分な治療を受けていない地域でも治療が受けやすくなっており、デジタルプラットフォームにより患者の参加、治療スケジュール、服薬管理が容易になっています。迅速な医薬品承認、非専門医への処方権限拡大、保険償還改革などの規制支援は、市場浸透を加速させています。医薬品イノベーションも重要な役割を果たしており、各社は乱用抑止製剤、インプラント、患者の転帰を改善する新しい送達方法などに投資しています。さらに、薬物使用の非犯罪化と矯正医療制度におけるOUD治療の利用拡大が、新たな制度需要を生み出しています。官民のパートナーシップと世界の啓発キャンペーンは、リソースをさらに動員し、さまざまなヘルスケア環境におけるOUD治療の利用可能性を拡大しています。これらの力が相まって、長期的な回復とシステムの回復力に焦点を当てた、強固で多面的な市場環境が醸成されつつあります。

セグメント

薬剤（ブプレノルフィン製剤、ナルトレキソン製剤、メタドン製剤、その他の薬剤）、投与経路（注射投与経路、経口投与経路、その他の投与経路）、流通チャネル（病院薬局、小売薬局、その他の流通チャネル）

調査対象企業の例

  • Acadia Healthcare
  • Alkermes plc
  • Amneal Pharmaceuticals, Inc.
  • BioDelivery Sciences International Inc.
  • Camurus AB
  • Collegium Pharmaceutical
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Johnson & Johnson
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Omeros Corporation
  • Opiant Pharmaceuticals, Inc.
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Titan Pharmaceuticals, Inc.
  • Viatris Inc.（Mylan N.V.）
  • West Pharmaceutical Services, Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32434

Global Opioid Use Disorder Market to Reach US$10.6 Billion by 2030

The global market for Opioid Use Disorder estimated at US$5.7 Billion in the year 2024, is expected to reach US$10.6 Billion by 2030, growing at a CAGR of 10.9% over the analysis period 2024-2030. Buprenorphine Drug, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Naltrexone Drug segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.8% CAGR

The Opioid Use Disorder market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global Opioid Use Disorder Market - Key Trends & Drivers Summarized

Why Is Opioid Use Disorder a Persistent Global Health Crisis Demanding Scalable Interventions?

Opioid Use Disorder (OUD) has escalated into a major public health emergency worldwide, particularly in North America, where synthetic opioids such as fentanyl have driven unprecedented overdose rates. The chronic, relapsing nature of OUD and its widespread socio-economic consequences have led to urgent calls for comprehensive treatment infrastructure and long-term care solutions. While awareness of the epidemic has grown significantly, so has the complexity of the crisis, which involves not only illicit drug use but also the over-prescription of opioids for pain management. With millions affected globally, healthcare systems are under pressure to adopt integrated, multi-modal approaches combining medication-assisted treatment (MAT), behavioral therapy, harm reduction, and social support. The stigma surrounding addiction, gaps in healthcare access, and the criminalization of substance use continue to hinder effective intervention strategies. However, increased public health funding, greater availability of treatment centers, and shifting perceptions of addiction as a treatable medical condition are fostering a more supportive environment for recovery. In this context, the market for OUD treatments is expanding as governments, healthcare providers, and private sector players prioritize scalable, evidence-based solutions that address both the physiological and psychological aspects of opioid dependency.

How Are Advancements in Treatment Modalities Shaping Recovery Outcomes?

The therapeutic landscape for Opioid Use Disorder is rapidly evolving, with innovation focused on improving the efficacy, safety, and accessibility of treatment options. Medication-assisted treatments (MATs) remain the cornerstone of OUD management, with methadone, buprenorphine, and naltrexone being widely used to reduce cravings, block opioid effects, and support recovery. Recent years have seen the development of extended-release formulations and implantable devices that ensure sustained medication delivery, reduce dosing frequency, and improve adherence-critical factors in long-term recovery. Novel combination therapies are also emerging to address both opioid dependence and co-occurring conditions such as depression or anxiety. Digital therapeutics and telehealth-based counseling platforms are gaining ground, especially post-COVID-19, enabling remote monitoring, therapy access, and adherence tracking. Wearable biosensors and mobile apps that provide real-time feedback and relapse alerts are being explored to support patients outside clinical environments. Additionally, research into vaccines and antagonists that block opioid receptors before the drug can exert its effects is progressing, holding promise for future prevention strategies. These advancements are not only improving patient outcomes but are also expanding treatment options in underserved and rural areas, where traditional infrastructure may be lacking.

What Systemic and Regional Factors Are Influencing Market Demand and Accessibility?

The demand for Opioid Use Disorder treatment solutions varies significantly across regions due to differences in healthcare infrastructure, policy frameworks, and socio-cultural attitudes toward addiction. In the United States and Canada, where the opioid crisis has reached epidemic levels, the focus is on expanding access to MAT, harm reduction services like naloxone distribution and safe injection sites, and integrating OUD treatment into primary care and emergency services. These countries have also seen strong government funding and regulatory support for new treatment products, including fast-tracked approvals and reimbursement programs. In contrast, developing nations often face limited access to both opioids for pain management and OUD therapies due to restrictive drug policies and underfunded healthcare systems. Stigma remains a barrier worldwide, often deterring individuals from seeking treatment or governments from investing in addiction care. However, global initiatives by organizations such as the WHO and UNODC are driving awareness and capacity-building efforts, particularly in Eastern Europe, Latin America, and parts of Asia. Meanwhile, criminal justice reforms in several countries are redirecting drug users toward treatment instead of incarceration, thereby expanding institutional demand for OUD solutions. These regional disparities and policy shifts are playing a pivotal role in shaping where and how the market for OUD treatment products and services is developing.

What Are the Primary Forces Driving Growth in the Opioid Use Disorder Market?

The growth in the Opioid Use Disorder market is driven by several factors related to rising disease prevalence, evolving treatment paradigms, technology integration, and policy shifts. A critical driver is the increasing global incidence of opioid addiction and related deaths, which is prompting urgent healthcare interventions and sustained public health funding. The widespread acceptance of medication-assisted treatment as the gold standard for OUD care is driving demand for methadone, buprenorphine, and naltrexone products, especially long-acting injectable formulations that improve adherence. Expansion of telehealth services is making treatment more accessible, particularly in rural and underserved communities, while digital platforms are facilitating patient engagement, therapy scheduling, and medication management. Regulatory support, including fast-track drug approvals, expanded prescribing authority for non-specialist providers, and insurance reimbursement reforms, is accelerating market penetration. Pharmaceutical innovation is also playing a key role, with companies investing in abuse-deterrent formulations, implants, and novel delivery methods to improve patient outcomes. Additionally, the decriminalization of substance use and the growing use of OUD treatment in correctional health systems are generating new institutional demand. Public-private partnerships and global awareness campaigns are further mobilizing resources and expanding the availability of OUD treatment across various healthcare settings. Collectively, these forces are fostering a robust, multi-faceted market environment focused on long-term recovery and systemic resilience.

SCOPE OF STUDY:

The report analyzes the Opioid Use Disorder market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Buprenorphine Drug, Naltrexone Drug, Methadone Drug, Other Drugs); Route of Administration (Injectable Route of Administration, Oral Route of Administration, Other Route of Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Acadia Healthcare
  • Alkermes plc
  • Amneal Pharmaceuticals, Inc.
  • BioDelivery Sciences International Inc.
  • Camurus AB
  • Collegium Pharmaceutical
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Johnson & Johnson
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Novartis AG
  • Omeros Corporation
  • Opiant Pharmaceuticals, Inc.
  • Orexo AB
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Titan Pharmaceuticals, Inc.
  • Viatris Inc. (Mylan N.V.)
  • West Pharmaceutical Services, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Opioid Use Disorder - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Escalating Overdose Rates Throw the Spotlight on Urgent Need for Scalable Opioid Use Disorder (OUD) Treatments
    • Rising Prevalence of Synthetic Opioids Like Fentanyl Spurs Growth in Medication-Assisted Treatment (MAT) Adoption
    • Policy Reforms and Federal Funding Initiatives Expand Addressable Market Opportunity for MAT Providers and Drug Developers
    • Integration of Telehealth in Behavioral Health Services Strengthens the Business Case for Remote OUD Treatment Models
    • Advancements in Long-Acting Injectables and Implants Drive Adoption of Adherence-Focused Treatment Solutions
    • Co-Occurrence of Mental Health Disorders Accelerates Demand for Integrated, Dual-Diagnosis Treatment Programs
    • Criminal Justice System Reforms Generate Opportunities for OUD Intervention in Correctional and Community Settings
    • Widening Provider Authorization and Prescribing Flexibility Propels Growth in Buprenorphine-Based Therapies
    • Increased Public Awareness and Stigma Reduction Campaigns Sustain Growth in Patient-Initiated Treatment Uptake
    • Digital Therapeutics and Mobile Recovery Apps Drive Innovation in Continuous OUD Support and Relapse Prevention
    • Growing Role of Pharmacies and Primary Care Clinics in MAT Delivery Expands Treatment Accessibility Across Communities
    • Emergence of Precision Medicine in Addiction Care Strengthens Development of Personalized OUD Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Opioid Use Disorder Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Opioid Use Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Opioid Use Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Buprenorphine Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Buprenorphine Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Naltrexone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Naltrexone Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Methadone Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Methadone Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Injectable Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Injectable Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • JAPAN
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • CHINA
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • EUROPE
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Opioid Use Disorder by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • FRANCE
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • GERMANY
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • UNITED KINGDOM
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Opioid Use Disorder Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Drug - Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Opioid Use Disorder by Drug - Percentage Breakdown of Value Sales for Buprenorphine Drug, Naltrexone Drug, Methadone Drug and Other Drugs for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Distribution Channel - Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Opioid Use Disorder by Distribution Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Opioid Use Disorder by Route Of Administration - Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Opioid Use Disorder by Route Of Administration - Percentage Breakdown of Value Sales for Injectable Route of Administration, Oral Route of Administration and Other Route of Administrations for the Years 2025 & 2030

IV. COMPETITION